Breast Cancer

Top news of the day from across the health care landscape.

Using real-time symptom reports, a well-trained classification algorithm can detect lymphedema more accurately than current clinical methods.

Atezolizumab (Tecentriq, Roche) plus chemotherapy nab-paclitaxel (Abraxane) met its co-primary endpoint of progression-free survival in patients with metastatic triple-negative breast cancer.

Atezolizumab (Tecentriq) plus chemotherapy nab-paclitaxel (Abraxane) significantly reduced the risk of disease worsening or death in patients with metastatic triple-negative breast cancer.

Researchers identified a trend in which higher body mass index was associated with lower breast cancer risk in women before menopause.

Researchers have identified a gene associated with the body’s circadian rhythm that may play a role in the development of breast cancer.

Top news of the day from across the health care landscape.

Researchers found that women with advanced triple-negative breast cancer who had inherited a BRCA mutation benefited more from the chemotherapy carboplatin than standard treatment.

A new study examines how chemoresistance evolves over time, which could lead to improved patient outcomes and survival.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

In the largest study of its kind, breast cancer survivors were not found to have a greater mortality risk due to heart disease than the general population.

The findings could lead to broader access to cancer drug Z-endoxifen for further clinical study

New drug shows promising signs of delaying the development of existing breast and lung cancers. .

A novel chimera targets the growth factors responsible for certain types of breast cancer.

Triple-negative and HER2-positive breast cancers may be unlikely to develop lymph node metastases.

Over the years, a number of landmark clinical studies on the management of breast cancer have been published, sharpening how patients are treated today.

Overweight patients with BRCA mutations may be more likely to develop breast cancer.

Top news of the week from Specialty Pharmacy Times.

Over the years, a number of landmark clinical studies on the management of breast cancer have been published, sharping how patients are treated today.

Breast cancer treatments may affect men differently than women.

Breast cancer survivors and insurance companies could gain a better understanding of mortality risk with a new model.

Olaparib (Lynparza) double objective response rate compared with other breast cancer drugs.

Officials with the FDA have approved ibalizumab-uiyk (Trogarzo, TaiMed Biologics), the first antiretroviral medication for adults with HIV who cannot be successfully treated with other therapies.

A new direct-to-consumer test analyzes saliva for 3 BRCA variants that may elevate the risk of various types of cancer.